Table 1. Logistic regression analysis of the correlation between XPD polymorphisms and neuroblastoma risk.
| Genotype | Cases (N=505) |
Controls (N=1070) |
P a | Crude OR (95% CI) |
P | Adjusted OR (95% CI) b |
P b |
| rs3810366 (HWE=0.143) | |||||||
| GG | 118 (23.37) | 285 (26.64) | 1.00 | 1.00 | |||
| GC | 261 (51.68) | 511 (47.76) | 1.23 (0.95-1.60) | 0.115 | 1.23 (0.95-1.60) | 0.120 | |
| CC | 126 (24.95) | 274 (25.61) | 1.11 (0.82-1.50) | 0.494 | 1.11 (0.82-1.50) | 0.502 | |
| Additive | 0.277 | 1.05 (0.91-1.22) | 0.498 | 1.05 (0.91-1.22) | 0.506 | ||
| Dominant | 387 (76.63) | 785 (73.36) | 0.165 | 1.19 (0.93-1.52) | 0.166 | 1.19 (0.93-1.52) | 0.171 |
| Recessive | 379 (75.05) | 796 (74.39) | 0.780 | 0.97 (0.76-1.23) | 0.781 | 0.97 (0.76-1.23) | 0.778 |
| rs13181 (HWE=0.971) | |||||||
| TT | 424 (83.96) | 905 (84.58) | 1.00 | 1.00 | |||
| TG | 75 (14.85) | 158 (14.77) | 1.01 (0.75-1.37) | 0.931 | 1.01 (0.75-1.36) | 0.943 | |
| GG | 6 (1.19) | 7 (0.65) | 1.83 (0.61-5.48) | 0.280 | 1.84 (0.61-5.50) | 0.278 | |
| Additive | 0.548 | 1.08 (0.83-1.41) | 0.586 | 1.08 (0.82-1.40) | 0.594 | ||
| Dominant | 81 (16.04) | 165 (15.42) | 0.752 | 1.05 (0.78-1.40) | 0.751 | 1.05 (0.78-1.40) | 0.762 |
| Recessive | 499 (98.81) | 1063 (99.35) | 0.274 | 1.83 (0.61-5.46) | 0.281 | 1.83 (0.61-5.49) | 0.279 |
| rs238406 (HWE=0.325) | |||||||
| GG | 133 (26.34) | 317 (29.63) | 1.00 | 1.00 | |||
| GT | 264 (52.28) | 516 (48.22) | 1.22 (0.95-1.57) | 0.121 | 1.22 (0.95-1.57) | 0.119 | |
| TT | 108 (21.39) | 237 (22.15) | 1.09 (0.80-1.47) | 0.595 | 1.09 (0.80-1.48) | 0.578 | |
| Additive | 0.282 | 1.05 (0.91-1.22) | 0.508 | 1.05 (0.91-1.22) | 0.492 | ||
| Dominant | 372 (73.66) | 753 (70.37) | 0.177 | 1.18 (0.93-1.49) | 0.178 | 1.18 (0.93-1.50) | 0.172 |
| Recessive | 397 (78.61) | 833 (77.85) | 0.732 | 0.96 (0.74-1.24) | 0.734 | 0.96 (0.74-1.24) | 0.749 |
| Combined effect of risk genotypes c | |||||||
| 0-1 | 247 (48.91) | 595 (55.61) | 1.00 | 1.00 | |||
| 2-3 | 258 (51.09) | 475 (44.39) | 0.013 | 1.31 (1.06-1.62) | 0.013 | 1.31 (1.06-1.62) | 0.013 |
a χ2 test for genotype distributions between neuroblastoma patients and cancer-free controls. b Adjusted for age and gender. c Risk genotypes were rs3810366 GC/GG, rs13181 GG and rs238406 GT/TT.